Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJKAQR)

Drug Name

L-790070 Drug Info

Synonyms

L-790070; CHEMBL303144; 189442-43-1; MRK-48; SCHEMBL4025110; BDBM15459; CTK4E0131; DTXSID50430959; 4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine; 4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine; 2-PYRIDINAMINE, 4-[1-METHYL-2-(4-PIPERIDINYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOL-5-YL]-N-[(1S)-1-PHENYLETHYL]-

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Investigative	[1]

Cross-matching ID

PubChem CID: 9806182
CAS Number: CAS 189442-43-1
TTD Drug ID: DMJKAQR

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Raf messenger RNA (Raf mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN2480	DMBR8NF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
SPN-803	DM8O2AQ	Parkinson disease	8A00.0	Phase 1	[2]
LXH254	DMQE9PS	Non-small-cell lung cancer	2C25.Y	Phase 1	[4]
ICo-007	DM79W8K	Diabetic macular edema	9B71.02	Phase 1	[5]
LErafAON	DMNHPOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
DEBROMOHYMENIALDISINE	DMDLER8	Discovery agent	N.A.	Investigative	[7]
ZM-336372	DMD5JYQ	Discovery agent	N.A.	Investigative	[8]
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine	DMDNG8F	Discovery agent	N.A.	Investigative	[9]
PLX-ORI3	DMZG1L5	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Raf messenger RNA (Raf mRNA)	TTAN5W2	RAF1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of ... J Med Chem. 2008 Jul 24;51(14):4122-49.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
3	Clinical pipeline report, company report or official report of Roche.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
6	Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
7	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
8	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
9	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.